Qiagen (QGEN) said Monday it has entered into partnerships with Tracer Biotechnologies and Foresight Diagnostics to advance the use of minimal residual disease testing in clinical trials, specifically covering solid tumors and hematological cancers.
Qiagen said it is working with Tracer to create companion diagnostics for minimal residual disease testing in solid tumors, while its collaboration with Foresight involves a kit-based version of Clarity assay, a circulating tumor DNA-based next-generation sequencing test for certain types of lymphoma.
Price: 44.88, Change: -0.25, Percent Change: -0.56
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.